Wearable Internet of Medical Things Sensor Devices, Artificial Intelligence-driven Smart Healthcare Services, and Personalized Clinical Care in COVID-19 Telemedicine

2020 ◽  
Vol 7 (2) ◽  
pp. 71
2021 ◽  
Vol 10 (10) ◽  
pp. 2112
Author(s):  
Tullika Garg ◽  
Courtney A. Polenick ◽  
Nancy Schoenborn ◽  
Jane Jih ◽  
Alexandra Hajduk ◽  
...  

Multiple chronic conditions (MCC) are one of today’s most pressing healthcare concerns, affecting 25% of all Americans and 75% of older Americans. Clinical care for individuals with MCC is often complex, condition-centric, and poorly coordinated across multiple specialties and healthcare services. There is an urgent need for innovative patient-centered research and intervention development to address the unique needs of the growing population of individuals with MCC. In this commentary, we describe innovative methods and strategies to conduct patient-centered MCC research guided by the goals and objectives in the Department of Health and Human Services MCC Strategic Framework. We describe methods to (1) increase the external validity of trials for individuals with MCC; (2) study MCC epidemiology; (3) engage clinicians, communities, and patients into MCC research; and (4) address health equity to eliminate disparities.


Author(s):  
G. Hampson ◽  
M. Stone ◽  
J. R. Lindsay ◽  
R. K. Crowley ◽  
S. H. Ralston

AbstractIt is acknowledged that the COVID-19 pandemic has caused profound disruption to the delivery of healthcare services globally. This has affected the management of many long-term conditions including osteoporosis as resources are diverted to cover urgent care. Osteoporosis is a public health concern worldwide and treatment is required for the prevention of further bone loss, deterioration of skeletal micro-architecture, and fragility fractures. This review provides information on how the COVID-19 pandemic has impacted the diagnosis and management of osteoporosis. We also provide clinical recommendations on the adaptation of care pathways based on experience from five referral centres to ensure that patients with osteoporosis are still treated and to reduce the risk of fractures both for the individual patient and on a societal basis. We address the use of the FRAX tool for risk stratification and initiation of osteoporosis treatment and discuss the potential adaptations to treatment pathways in view of limitations on the availability of DXA. We focus on the issues surrounding initiation and maintenance of treatment for patients on parenteral therapies such as zoledronate, denosumab, teriparatide, and romosozumab during the pandemic. The design of these innovative care pathways for the management of patients with osteoporosis may also provide a platform for future improvement to osteoporosis services when routine clinical care resumes.


2021 ◽  
Vol 1 (1) ◽  
Author(s):  
Sumarno Adi Subrata ◽  
Jonathan Bayuo ◽  
Busra Sahin

The growing evidence and technology in healthcare lead to an improvement in the patient's health across a continuum of services in clinical and community settings. A multidisciplinary team should work in tandem on this phenomenon. Therefore, innovative healthcare technology must be designed intensively to optimize productivity and provide new insight along with support the standard treatment for particular diseases. In the coming years, technology is needed to change the way of caring for the patient. This is a fundamental aspect because the recent technology has shaped up in front of our practice with advances in digital healthcare services, such as 3D printing, robotics, nanotechnology and even artificial intelligence (The Medical Futurist, 2021). To respond to this, updated studies should be developed and published focusing on innovative technology including in Medicine, Nursing, Pharmacy, and other health-related topics.


2020 ◽  
Author(s):  
Sandeep Reddy ◽  
Sonia Allan ◽  
Simon Coghlan ◽  
Paul Cooper

The re-emergence of artificial intelligence (AI) in popular discourse and its application in medicine, especially via machine learning (ML) algorithms, has excited interest from policymakers and clinicians alike. The use of AI in clinical care in both developed and developing countries is no longer a question of ‘if?’ but ‘when?’. This creates a pressing need not only for sound ethical guidelines but also for robust governance frameworks to regulate AI in medicine around the world. In this article, we discuss what components need to be considered in developing these governance frameworks and who should lead this worldwide effort?


Sign in / Sign up

Export Citation Format

Share Document